BRCA2 antibody (AA 21-130)
-
- Target See all BRCA2 Antibodies
- BRCA2 (Breast Cancer 2, Early Onset (BRCA2))
-
Binding Specificity
- AA 21-130
-
Reactivity
- Human
-
Host
- Rabbit
-
Clonality
- Polyclonal
-
Conjugate
- This BRCA2 antibody is un-conjugated
-
Application
- Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))
- Cross-Reactivity
- Human
- Predicted Reactivity
- Mouse,Rat,Dog,Cow,Horse,Chicken,Rabbit
- Purification
- Purified by Protein A.
- Immunogen
- KLH conjugated synthetic peptide derived from human BRCA2
- Isotype
- IgG
-
-
- Application Notes
-
WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 - Restrictions
- For Research Use only
-
- by
- Alamo Laboratories Inc
- No.
- #029807
- Date
- 08/26/2014
- Antigen
- Lot Number
- 101020
- Method validated
- Western Blotting
- Positive Control
- MCF7 cells
- Negative Control
- [CAPAN1 cells] (http://www.pnas.org/content/98/15/8644.full.pdf)
- Notes
- A strong band was observed in the positive control sample at the correct molecular weight. No bands were observed in the negative control sample.
- Primary Antibody
- Antigen: Breast Cancer 2, Early Onset (BRCA2)
- Catalog number: ABIN673434
- Lot number: 101020
- Antibody Dilution: 1:200
- Secondary Antibody
- Antigen: Goat Anti-Rabbit IgG (H + L)-HRP Conjugate
- Lot number: L170-6515
- Antibody Dilution: 1:10,000
- Full Protocol
- 1. The cell extracts were heated at 95°C for 5 minutes in 1X SDS Sample Buffer containing 1% SDS and 1.25% β-mercaptoethanol.
- 2. 15 μl of heated culture-media were loaded and resolved on 8-16% SDS-polyacrylamide gel.
- 3. The Thermo Scientific - Spectra Multicolor Broad Range (Cat # 26634) were used as molecular mass markers.
- 4. Proteins were then transferred onto PVDF membrane by wet transfer and protein transfer was confirmed with Ponceau-S staining.
- 5. The PVDF membrane was incubated with 25 ml of blocking buffer [Tris Buffered Saline, pH 7.4 plus 0.1% TW20 (TBST)] containing 5% (W/V) BSA at room temperature for 1 hour.
- 6. The membrane was rinsed with TBST once.
- 7. The membrane was immersed with the protein side up in the primary antibody solution in TBST containing 5% (W/V) BSA and incubated for 10 hours at 4°C.
- 8. The membrane was rinsed in TBST thrice for 5 minutes each.
- 9. The membrane was incubated in the HRP-conjugated secondary antibody solution in TBST containing 5% (W/V) BSA and incubated for 1 hour at room temperature (~26°C) with gentle agitation.
- 10. The membrane was rinsed thrice TBST thrice for 5 minutes each.
- 11. The membrane was rinsed in TBS twice for 30 seconds each.
- 12. Signals were detected with ECL-2 Substrate. The blot was scanned for 5 minutes.
- 13. The membrane was rinsed three times TBST.
- 14. Incubated in Acidic Glycine Stripping Buffer at room temperature with gentle agitation for 3 times, 10 minutes each.
- 15. The membrane was washed in TBST 2 times for 10 minutes each.
- 16. Repeated Steps 5-12 with the loading control antibody (for Anti-actin) and its matching secondary antibody.
- Experimental Notes
- - No experimental challenges noted.
Validation #029807 (Western Blotting)Validation ImagesFull Methods -
- Format
- Liquid
- Concentration
- 1 μg/μL
- Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
- Preservative
- ProClin
- Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- Storage
- 4 °C,-20 °C
- Storage Comment
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
- Expiry Date
- 12 months
-
- Target
- BRCA2 (Breast Cancer 2, Early Onset (BRCA2))
- Alternative Name
- BRCA2 (BRCA2 Products)
- Background
-
Synonyms: FAD, FACD, FAD1, GLM3, BRCC2, FANCD, PNCA2, FANCD1, BROVCA2, Breast cancer type 2 susceptibility protein, Fanconi anemia group D1 protein, BRCA2
Background: Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. Part of a PALB2-scaffolded HR complex containing RAD51C and which is thought to play a role in DNA repair by HR. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. May play a role in the extension step after strand invasion at replication-dependent DNA double-strand breaks, together with PALB2 is involved in both POLH localization at collapsed replication forks and DNA polymerization activity. In concert with NPM1, regulates centrosome duplication. Interacts with the TREX-2 complex (transcription and export complex 2) subunits PCID2 and DSS1, and is required to prevent R-loop-associated DNA damage and thus transcription-associated genomic instability. Silencing of BRCA2 promotes R-loop accumulation at actively transcribed genes in replicating and non-replicating cells, suggesting that BRCA2 mediates the control of R-loop associated genomic instability, independently of its known role in homologous recombination (PubMed:24896180).
- Gene ID
- 675
- UniProt
- P51587
- Pathways
- DNA Damage Repair, M Phase, Maintenance of Protein Location
-